AbbVie Inc.'s stock rose 4% early Friday, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025.

AbbVie (ABBV) stock gains as company sets 2025 earnings outlook in line with expectations after Q4 revenue beat and despite quarterly loss. Read more here.

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

With all the rapid advancements in technology and the race to be the next global disruptor through AI technology, Omar ...

StockNews.com initiated coverage on shares of Ambev (NYSE:ABEV – Free Report) in a research note released on Sunday. The brokerage issued a buy rating on the stock. Separately, Bank of America cut ...

On Friday, BofA Securities adjusted its stance on Ambev S.A. (ABEV3:BZ) (NYSE: ABEV), downgrading the company's stock rating from Buy to Neutral. The firm also revised its price target for the ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More AI or Not, a widely covered AI fraud detection platform, has raised $ ...

On Friday, BofA Securities adjusted its stance on Ambev S.A. (ABEV3:BZ) (NYSE: ABEV), downgrading the company's stock rating from Buy to Neutral. The firm also revised its price target for the ...